Tag: casdatifan,

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily…

Business Wire Business Wire